Treatment Clinical Trials for Uterine Sarcoma
Clinical trials are research studies that involve people. The clinical trials on this list are for uterine sarcoma treatment. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Nivolumab in Treating Patients with Metastatic or Recurrent Uterine Cancer
This phase II trial studies how well nivolumab works in treating patients with uterine cancer that has spread to other places in the body or come back after a period of improvement. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Location: 7 locations
Short Course Vaginal Cuff Brachytherapy in Treating Patients with Stage I-II Endometrial Cancer
This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating patients with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells.
Location: 3 locations
A Phase 1 / 2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
This is a two-part Phase 1 / 2 dose escalation and dose expansion study of the GMCSF-encoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.
Location: 3 locations
HER2-Specific T Cells in Treating Patients With HER2-Positive Refractory or Metastatic Sarcoma
The purpose of this study is to obtain blood from sarcoma patients to see if researchers can make cells that are able to fight and kill sarcoma cells. If researchers are able to do this, these T cells may be offered back to the patient in the future if the patient is eligible to participate in a treatment research study using these cells. Should this occur, as separate consent will be obtained that will provide much more information about the risks and potential benefits of this treatment. The purpose of this study is also to find the largest safe dose of chimeric T cells, to learn what the side effects are, and to see whether this therapy might help patients with sarcoma.
Location: 3 locations
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
This phase I / II trial studies the side effects and best dose of vorinostat when given together with gemcitabine hydrochloride and docetaxel and to see how well it works in treating patients with soft tissue sarcoma that is metastatic or cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells.
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
This phase I trial studies radiation therapy, paclitaxel, and carboplatin in treating patients with uterine cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or stopping them from dividing. Giving radiation with chemotherapy may kill more tumor cells.
Location: Montefiore Medical Center-Weiler Hospital, Bronx, New York
Phase 1 / 2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
The purpose of Part 1 (Phase 1b) is to evaluate the general safety and tolerability of repeated 21-day cycles of AL3818 therapy, and to reevaluate the maximum tolerated dose (MTD). The purpose of Part 2 (Phase 2a) is to evaluate the efficacy of repeated 21-day cycles of AL3818 therapy preliminary efficacy of AL3818 in subjects with recurrent or metastatic endometrial, ovarian or cervical cancer.
Location: See Clinical Trials.gov